One-step synthesis of carbon-13-labeled globotriaosylsphingosine (lyso-Gb3), an internal standard for biomarker analysis of Fabry disease

被引:3
|
作者
Hong, Xinying [1 ]
Gelb, Michael H. [1 ,2 ]
机构
[1] Univ Washington, Dept Chem, Campus Box 351700, Seattle, WA 98195 USA
[2] Univ Washington, Dept Biochem, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
Fabry disease; Lysosomal storage disease; Biomarker; Tandem mass spectrometry; Lyso-Gb3;
D O I
10.1016/j.ymgme.2018.08.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Globotriaosylsphingosine (lyso-Gb3) is a well-established biomarker for diagnosis and prognosis of Fabry disease. This biomarker is measured in biological samples by liquid chromatography-tandem mass spectrometry using an internal standard. The ideal internal standard is a variant of lyso-Gb3 substituted with heavy isotopes, but the total synthesis of such a compound is very labor intensive. In this report, we describe a simple, one-step synthesis of lyso-Gb3 labeled with carbon-13 in all of the galactosyl carbons.
引用
收藏
页码:292 / 294
页数:3
相关论文
共 6 条
  • [1] How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?
    Auray-Blais, Christiane
    Ntwari, Aime
    Clarke, Joe T. R.
    Warnock, David G.
    Oliveira, Joao Paulo
    Young, Sarah P.
    Millington, David S.
    Bichet, Daniel G.
    Sirrs, Sandra
    West, Michael L.
    Casey, Robin
    Hwu, Wuh-Liang
    Keutzer, Joan M.
    Zhang, X. Kate
    Gagnon, Rene
    CLINICA CHIMICA ACTA, 2010, 411 (23-24) : 1906 - 1914
  • [2] Plasma lyso-Gb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes
    Nowak, Albina
    Mechtler, Thomas P.
    Desnick, Robert J.
    Kasper, David C.
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S103 - S104
  • [3] LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease
    Boutin, Michel
    Gagnon, Rene
    Lavoie, Pamela
    Auray-Blais, Christiane
    CLINICA CHIMICA ACTA, 2012, 414 : 273 - 280
  • [4] Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation
    Chien, Yin-Hsiu
    Bodamer, Olaf A.
    Chiang, Shu-Chuan
    Mascher, Hermann
    Hung, Christina
    Hwu, Wuh-Liang
    JOURNAL OF INHERITED METABOLIC DISEASE, 2013, 36 (05) : 881 - 885
  • [5] Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
    Maruyama, Hiroki
    Miyata, Kaori
    Mikame, Mariko
    Taguchi, Atsumi
    Guili, Chu
    Shimura, Masaru
    Murayama, Kei
    Inoue, Takeshi
    Yamamoto, Saori
    Sugimura, Koichiro
    Tamita, Koichi
    Kawasaki, Toshihiro
    Kajihara, Jun
    Onishi, Akifumi
    Sugiyama, Hitoshi
    Sakai, Teiko
    Murata, Ichijiro
    Oda, Takamasa
    Toyoda, Shigeru
    Hanawa, Kenichiro
    Fujimura, Takeo
    Ura, Shigehisa
    Matsumura, Mimiko
    Takano, Hideki
    Yamashita, Satoshi
    Matsukura, Gaku
    Tazawa, Ryushi
    Shiga, Tsuyoshi
    Ebato, Mio
    Satoh, Hiroshi
    Ishii, Satoshi
    GENETICS IN MEDICINE, 2019, 21 (01) : 44 - 52
  • [6] Volumetric absorptive microsampling coupled with UHPLC-MS/MS for the determination of Lyso-Gb3 as Fabry disease diagnostic biomarker
    Mohamed, Susan
    Perrone, Alessandro
    Cancellerini, Chiara
    Esposito, Erika
    Caravelli, Alice
    Donadio, Vincenzo
    Liguori, Rocco
    Contin, Manuela
    Fiori, Jessica
    MICROCHEMICAL JOURNAL, 2024, 200